Contact
searchSearch
HMP Global
Login

Breast Cancer Excellence Forum

Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Seth Wander, MD, PhD; Rachel Abelman, MD, Massachusetts General Brigham Cancer Center
Videos
Omitting Carboplatin from Neoadjuvant Regimen for Patients With HER2-Positive Early Breast Cancer
07/31/2025
Seth Wander, MD
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth...
07/31/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Improving Abemaciclib Tolerability With a Dose Escalation Strategy for Early Stage HR-Positive, HER2-Negative Breast Cancer
06/11/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares...
06/11/2025
Oncology
Antonio Marra, MD, European Institute of Oncology
Videos
Prognostic Significance of Germline BRCA Status in HR-Positive, HER2-Negative Early Breast Cancer
06/10/2025
Antonio Marra, MD
Antonio Marra, MD, discusses the impact of germline BRCA status on distant relapse-free survival and invasive disease-free survival among patients with early HR-positive, HER2-negative breast cancer.
Antonio Marra, MD, discusses the impact of germline BRCA status on distant relapse-free survival and invasive disease-free survival among patients with early HR-positive, HER2-negative breast cancer.
Antonio Marra, MD, discusses the...
06/10/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Sequential Use of Antibody-Drug Conjugates for Patients With Breast Cancer
03/25/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD,...
03/25/2025
Oncology
Heather Moore, PharmD, BCOP, CPP, Duke Cancer Center
Videos
Managing Adverse Events in Breast Cancer Treatment
03/25/2025
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP,...
03/25/2025
Oncology
William Gradishar, MD, Robert H Lurie Comprehensive Cancer Center
Videos
Extended Endocrine Therapy for Patients With Hormone Receptor-Positive, Early-Stage Breast Cancer
03/06/2025
William Gradishar, MD
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses...
03/06/2025
Oncology
Aditya Bardia, MD
Videos
Impact of Datopotamab Deruxtecan Approval for HR-Positive, HER2-Negative Breast Cancer
01/27/2025
Aditya Bardia, MD
Aditya Bardia, MD, MPH, discusses results from the TROPION-Breast01 trial which led to the recent FDA approval of datopotamab deruxtecan for patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
Aditya Bardia, MD, MPH, discusses results from the TROPION-Breast01 trial which led to the recent FDA approval of datopotamab deruxtecan for patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
Aditya Bardia, MD, MPH,...
01/27/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
Inavolisib for PIK3CA-Mutant Metastatic Breast Cancer
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
Agents Targeting PI3K Signaling in HR-Positive Metastatic Breast Cancer
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
The PI3 Kinase Pathway in Metastatic HR-Positive Breast Cancer
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology

Recent News

News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
News
Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer
09/12/2025
Stephanie Holland
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy...
09/12/2025
Oncology
News
Durvalumab Plus Platinum-Based Chemotherapy for Treatment-Naive Patients With Extensive-Stage Small Cell Lung Cancer
09/10/2025
Stephanie Holland
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory...
09/10/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
FDA Approval
FDA Approves Selumetinib Granules and Capsules for Pediatric Patients With NF1-Associated Symptomatic and Inoperable Plexiform Neurofibromas
09/10/2025
Stephanie Holland
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib...
09/10/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
News
Dual Immune Checkpoint Blockade Plus Radiotherapy Fails to Improve Outcomes Among Newly Diagnosed Patients With MGMT-Unmethylated Glioblastoma
08/28/2025
Stephanie Holland
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a...
08/28/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
News
Afatinib Plus Carboplatin and Pemetrexed Demonstrates Efficacy, Safety Among Patients WIth Advanced EGFR-Mutated Non-Small Cell Lung Cancer
08/27/2025
Stephanie Holland
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the...
08/27/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use